PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Pelthos Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$20.26+0.11 (+0.55%)
Close on Oct 19, 2026
- Market cap
- $71.71M
- P/E (TTM)
- –
- Dividend yield
- –
Pelthos Therapeutics Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| Commercial operations | $16.21M | $0 | 96.5% | – |
| Research and Development operations | $589.00K | $0 | 3.5% | – |
By product or service
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| Net product revenues | $16.21M | $0 | 96.5% | – |
| License and collaboration revenues | $589.00K | $0 | 3.5% | – |
By region
From the segment and revenue-disaggregation notes of Pelthos Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.